Back to mobile site

JPMorgan Starts Neurogene (NGNE) at Overweight

October 8, 2026 3:14 AM EDT Send to a Friend
JPMorgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ: NGNE) with a Overweight rating and a price target of $60.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login